The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
 
Alison Zhang
Honoraria - Astellas Pharma; AstraZeneca; Bayer; MSD Oncology; Mundipharma; Pfizer (Inst)
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer; Janssen Oncology; Merck; Merck Sharp & Dohme; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; MSD Oncology
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Hayley Thomas
No Relationships to Disclose
 
Ronan McLaughlin
No Relationships to Disclose
 
Thean Tan
No Relationships to Disclose
 
David Pook
Honoraria - Astellas Pharma; Bayer; Bayer; Janssen; Merck/Pfizer
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Cipla; Eisai; Janssen; Merck; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Merck/Pfizer; Merck/Pfizer; Pfizer; Pfizer (Inst)
Speakers' Bureau - Merck
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck/Pfizer; Merck/Pfizer; MSD; Pfizer; Pfizer
 
Gavin Marx
No Relationships to Disclose
 
Robert Zielinski
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bayer
Speakers' Bureau - Janssen
 
Shahneen Sandhu
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst); Roche/Genentech (Inst); Skyline Diagnostics (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Alastair Thomson
Honoraria - Accord Healthcare; Exact Sciences; Gilead Sciences; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Exact Sciences; Gilead Sciences; MSD; Novartis; Seagen
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca/UK; Bristol-Myers Squibb; EUSA Pharma; Exact Sciences; Gilead Sciences; Ipsen; Lilly; Menarini; MSD; Novartis; Stemline Therapeutics
 
M. Reaume
Honoraria - Astellas Pharma; Bayer; Bristol Myers Squibb; Merck
 
Scott North
Honoraria - Astellas Pharma; BMS; Janssen-Ortho; Merck; Pfizer; Roche Canada; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Pfizer; Roche Canada; Sanofi
Research Funding - AstraZeneca (Inst); Exelixis (Inst); Merck (Inst)
 
John McCaffrey
No Relationships to Disclose
 
Raymond McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Nicola Lawrence
Employment - Canopy Cancer Care
Stock and Other Ownership Interests - Canopy Cancer Care
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - ANZUP; Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - ANZUP; Astellas Pharma; Bayer; Bayer (Inst); Janssen
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; Bayer; Bayer (Inst); Imagion Biosystems
Research Funding - Astellas Pharma; Bayer (Inst); RedHill Biopharma (Inst)
Patents, Royalties, Other Intellectual Property - Provisional patent Australian No. 2022902527 Prognostic Markers (plasma lipid prognostic signature in metastatic prostate cancer). Inventors: Horvath L, Meikle P, Scheinberg S, Lin HM, Sullivan D The patent is owned by the Chris O'Brien Lifehouse (my (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology; Pfizer
 
Simon Chowdhury
Stock and Other Ownership Interests - Telix Pharmaceuticals
Honoraria - Novartis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Huma; Janssen-Cilag; Novartis; Pfizer; Remedy Bio; Telix Pharmaceuticals
Speakers' Bureau - Janssen-Cilag; Pfizer
 
Kim Chi
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Janssen; Merck; Novartis; Pfizer; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; Janssen; Merck; POINT Biopharma; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; CellCentric; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
No Relationships to Disclose